by Raynovich Rod | Jun 4, 2013 | BIOgraph, Biopharmaceuticals
Apparently ASCO Is “Sell On the News” Trigger Another lackluster trading day with profit taking; the IBB is down 2.3% and trading near its May bottom with a pronounced topping pattern.Moreover many funds and indices now own biotech stocks so without the...
by Raynovich Rod | Jun 3, 2013 | BIOgraph, Biopharmaceuticals
Sell On ASCO News Due to High Expectations? Large Cap Drugs Outperform Biotechs As we move through the first day of ASCO and much anticipated clinical developments the market should not be surprised that large cap drug stocks are also major biotech stocks: Bristol...
by Raynovich Rod | Jun 3, 2013 | 2024 Rayno Biopharmaceuticals Portfolio, BIOgraph, Biopharmaceuticals
Raise More Cash- No Change in Rayno Biopharma Portfolio Last month we raised the yellow flag on the biotech sector because of a choppy tape, new highs with weakness in MO (Momentum) plays and the anticipation of ASCO news that could trigger a “sell on the...
by Raynovich Rod | May 29, 2013 | BIOgraph, Biopharmaceuticals
Biopharmaceutical Stocks Sell-Off with Large Cap Drug Stocks High Flyers du jour-AEGR,INFI 10 Year Treasury Hits 2.13 Yield Caution-no new buys and all portfolio positions on hold Large cap drug stocks were the surprising loser today along with the healthcare sector...
by Raynovich Rod | May 28, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, BIOgraph
Impressive Rally in Diagnostics and Tools Stocks The NASDAQ rally is beginning to fade now up only 17 pts after hitting a high of 3510 at 10 am EDT. However many Life Science Tools and Diagnostics stocks are having a strong day. We recently featured 3 micro-cap...
by Raynovich Rod | May 22, 2013 | BIOgraph, Biopharmaceuticals
Biotechs Bounce Back After Deep Dive Unless you were trading at the open today and covered your shorts you could have been whipsawed in a volatile market that had NASDAQ down to the 3425 level. Many biotech stocks recovered today so no technical damage. The IBB was...
by Raynovich Rod | May 22, 2013 | BIOgraph, Reading List
Cancer’s Bitter Medicine Alex Philippidis in today’s Genetic Engineering News provides an excellent review of the treatment costs for CML (chronic myeloid leukemia) which can exceed $100k/year. However concern about the costs of cancer treatment has not...
by Raynovich Rod | May 20, 2013 | BIOgraph, Reading List
1999 Biotech Superstar Got Bailed Out By Anthrax antitoxin?! The famous Company that was going to revolutionize drug discovery was saved in 2003 by a government funded bioterror program for Anthrax and later a Lupus drug. Anthrax drug brings $334 million to Pentagon...
by Raynovich Rod | May 15, 2013 | BIOgraph, Clinical Diagnostics and Tools
Biomarker Products for Cardiovascular Disease and Cancer This is the third article on Emerging Biomarker Companies. See 11/15/12 Update The synergies between diagnostics and drugs are growing as more treatment options require better data for cost-effective, targeted...
by Raynovich Rod | May 14, 2013 | BIOgraph, Biopharmaceuticals
BioBubble with No Trouble? Another green screen today with the usual suspects running in Rayno Biopharmaceuticals helped by the Bank of America Health Care Conference. Alexion (ALXN) up 2.86%, Biogen Idec (BIIB) up 3.19%, Gilead (GILD) up 3.27%, Pharmacyclics (PCYC)...
